Polyunsaturated omega-3 fatty acids and Systemic Lupus Erythematosus: What do we know?;Ácidos graxos poli-insaturados ômega-3 e lúpus eritematoso sistêmico: O que sabemos?

Revista Brasileira de Reumatologia

Volumn 54, Issue 6, 2014, Pages 459-466

  Borges, Mariane Curado ^a   Santos, Fabiana Miranda Moura ^a   Telles, Rosa Weiss ^a   Correia, Maria Isabel Toulson Davisson ^a   Lanna, Cristina Costa Duarte ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antioxidants and diet; Docosahexanoic acid (DHA); Eicosapentanoic acid (EPA); Polyunsaturated fatty acids omega 3; Systemic lupus erythematous (SLE)

Indexed keywords

ANTIOXIDANT; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; ANTIINFLAMMATORY AGENT;

CLINICAL FEATURE; CLINICAL STUDY; DIET; DISEASE ACTIVITY; DISEASE ASSOCIATION; FAT INTAKE; HUMAN; INFLAMMATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANTI-INFLAMMATORY AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84920168876     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbr.2013.12.002     Document Type: Short Survey

References (51)

1. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infartomiocardico. Dietary supplementation with n-3polyunsaturated fatty acids and vitamin E after myocardialinfarction: results of the GISSI-Prevenzione trial. Lancet.1999;354:447-55.
2. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. N-3 Fatty acids from fish orfish-oil supplements, but not alpha-linolenic acid, benefitcardiovascular disease outcomes in primary-andsecondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84:5-17.
3. Kromhout D, Giltay EJ, Geleijnse JM. N-3 fatty acids andcardiovascular events after myocardial infarction. N Engl JMed. 2010;363:2015-26.
4. Lorente-Cebrián S, Costa AG, Navas-Carretero S, Zabala M, Martínez JA, Moreno-Aliaga MJ. Role of omega-3 fatty acidsin obesity, metabolic syndrome, and cardiovascular diseases:a review of the evidence. J Physiol Biochem. 2013;69:633-51.
5. Calviello G, Su HM, Weylandt KH, Fasano E, Serini S, Cittadini A. Experimental evidence of ω-3 polyunsaturated fatty acidmodulation of inflammatory cytokines and bioactive lipidmediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int.2013;2013:743171.
6. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, Martin A, Aandres-Lacueva C, Senin U, Guralnik JM. Relationship of plasma polyunsaturated fatty acids tocirculating inflammatory markers. JCEM. 2006;91:439-46.
7. Schwab JM, Serhan CN. Lipoxins and new lipid mediators inthe resolution of inflammation. Curr Opin Pharmacol.2006;6:414-20.
8. Thies F, Miles EA, Nebe-von-Caron G, Powell JR, Hurst TL, Newsholme EA, Calder PC. Influence of dietarysupplementation with long-chain n-3 or n-6 polyunsaturatedfatty acids on blood inflammatory cell populations andfunctions and on plasma soluble adhesion molecules inhealth adults. Lipids. 2001;36:1183-93.
9. Trebble T, Arden NK, Stroud MA, Wootton SA, Burdge GC, Miles EA, Ballinger AB, Thompson RL, Calder PC. Inhibitionof tumour necrosis factor-α and interleukin-6 production bymononuclear cells following dietary fish-oil supplementationin healthy men and response to antioxidantco-supplementation. Brit J Nutr. 2003;90:405-12.
10. Wallace FA, Miles EA, Calder PC. Comparison of the effects oflinseed oil and different doses of fish oil on mononuclear cellfunction in healthy human subjects. Brit J Nutr.2003;89:679-89.
11. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products ofomega-3 fatty acid transformation circuits initiated by aspirintreatment that counter proinflammatory signals. J Exp Med.2002;196:1025-37.
12. Hong S, Gronert K, Devchand P, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated fromdocosahexaenoic acid in murine brain, human blood and glialcells: autocoids in anti-inflammation. J Biol Chem.2003;278:14677-87.
13. Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2:355-74.
14. Lau CS, Morley KD, Belch JJ. Effects of fish oil supplementationon non-steroidal anti-inflammatory drug requirement inpatients with mild rheumatoid arthritis-a double-blindplacebo controlled study. Br J Rheumatol. 1993;32:982-9.
15. Berbert AA, Kondo CR, Almendra CL, Matsuo T, Dichi I. Supplementation of fish oil and olive oil in patients withrheumatoid arthritis. Nutrition. 2005;21:131-6.
16. Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fattyacids and the treatment of rheumatoid arthritis:a meta-analysis. Arch Med Res. 2012;43:356-62.
17. Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemiclupus erythematosus. Kidney Int. 1989;36:653-60.
18. Westberg G, Tarkowski A. Effect of Max EPA in patients with SLE. A double-blind, crossover study. Scand J Rheumatol.1990;19:137-43.
19. Clark WF, Parbtani A, Naylor CD, Levinton CM, Muirhead N, Spanner E, Huff MW, Philbrick DJ, Holub BJ. Fish oil in lupusnephritis: clinical findings and methodological implications. Kidney Int. 1993;44:75-86.
20. Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL. The clinical effect of dietary supplementationwith omega-3 fish oils and copper in systemic lupuserythematosus. J Rheumatol. 2004;31:1551-6.
21. Nakamura N, Kumasaka R, Osawa H, Yamabe H, Shirato K, Fujita T, Murakami R, Shimada M, Nakamura M, Okumura K, Hamazaki K, Hamazaki T. Effects of eicosapentaenoic acidson oxidative stress and plasma fatty acid composition inpatients with lupus nephritis. In vivo. 2005;19:879-82.
22. Wright SA, ÓPrey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, Johnston DG, Finch MB, Bell AL, McVeigh GE. Arandomised interventional trial of w-3 polyunsaturated acidson endothelial function and disease activity in systemiclupus erythematosus. Ann Rheum Dis. 2008;67:841-8.
23. Aghdassi E, L. Ma DW, Morrison S, Hillyer LM, Clarke S, Gladman DD, Urowitz MB, Fortin PR. Alterations in circulatingfatty acid composition in patients with systemic lupuserythematosus: a pilot study. JPEN. 2011;35:198-208.
24. Elkan AC, Anania C, Gustafsson T, Jogestrand T, Hafstrõm I, Frostegard J. Diet and fatty acid pattern among patientswith SLE: associations with disease activity, blood lipidsand atherosclerosis. Lupus. 2012;21:1405-11.
25. Bello KJ, Fang H, Fazeli P, Bolad W, Corretti M, Magder LS, Petri M. Omega-3 in SLE: a double-blind, placebo-controlledrandomized clinical trial of endothelial dysfunction anddisease activity in systemic lupus erythematosus. Rheumatol Int. 2013. Epub ahead of print.
26. Vasudevan A, Ginzler E. Clinical features of systemic lupuserythematosus. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, editors. Rheumatology. Philadelphia: Mosby Elsevier; 2011.
27. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupuserythematosus: allergies, infections, and family history. J Clin Epidemiol. 2002;55:982-9.
28. Yu SL, Kuan WP, Wong CK, Li EK, Tam LS. Immunopathologicalroles of cytokines, chemokines, signaling molecules, andpattern-recognition receptors in systemic lupuserythematosus. Clin Dev Immunol. 2012;2012:715190.
29. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, JA J. Clinical criteria for systemic lupuserythematosus precede diagnosis, and associatedautoantibodies are present before clinical symptoms. Arthritis Rheum. 2007;56:2344-51.
30. Jacob N, Stohl W. Cytokine disturbances in systemic lupuserythematosus. Arthritis Res. 2011;13:228.
31. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupuserythematosus. J Biomed Biotechnol. 2011;2011:432595.
32. Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro andanti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012:34714.
33. Bhangle S, Kolasinski SL. Fish oil in rheumatic diseases. Rheum Dis Clin N Am. 2011;37:77-84.
34. Kronmann N, Green A. Epidemiological studies in the Upernavik district, Greenland: incidence of some chronicdiseases 1950-1974. Acta Med Scand. 1980;208:401-6.
35. Tilley SL, Coffman TM, Koller BH. Mixed messages:modulation of inflammation and immune responsesby prostaglandins and thromboxanes. J Clin Invest.2001;108:15-23.
36. Bistrian BR. Clinical aspects of essential fatty acidmetabolism: Jonathan Rhoads lecture. JPEN. 2003;27:168-75.
37. Leonard AE, Pereira SL, Sprecher H, Huang HS. Elogationof long-chain fatty acids. Prog Lipid Res. 2004;43:36-54.
38. Samuelsson B. Leukotrienes: mediators of immediatehyersensitivity reactions and inflammation. Science.1983;220:568-75.
39. Salmmon JA, Higgs GA. Prostaglandins and leukotrienes asinflammatory mediators. Br Med Bull. 1987;43:285-96.
40. Miles EA, Calder PC. Influence of marine n-3 polyunsaturatedfatty acids on immune function and systematic review oftheir effects on clinical outcomes in rheumatoid arthritis. Br JNutr. 2012;107:S171-84.
41. Caughey GE, Pouliot M, Cleland LG, James MJ. Regulationof tumor necrosis factor-alpha and IL-1 beta synthesisby thromboxane A2 in nonadherent human monocytes. J Immunol. 1997;158:351-8.
42. Hugues DA, Pinder AC. n-3 polynsaturated fatty acids inhibitthe antigen-presenting function of human monocytes. Am JClin Nutr. 2000;71:357S-60S.
43. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA, Libby P. The omega-3 fatty acid docosahexaenoate reducescytokine-induced expression of proatherogenic anproinflammatory proteins in human endothelial cells. Arterioscler Thromb. 1994;14:1829-36.
44. Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in bitrohuman endothelial cell production of interleukin-6. Adv Exp Biol Med. 1997;400:589-97.
45. Zhao Y, Joshi-Barve S, Barve S, Chen LH, Barve S, Chen LH. Eicosapentaenoic acid prevents LSP-induced TNF-alphaexpression by preventing NF-kappa B activation. J Am Coll Nutr. 2004;23:71-8.
46. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL. Oral (n-3) fattyacid supplementation suppresses cytokine production andlymphocyte proliferation: comparison between youngand older woman. J Nutr. 1991;121:547-55.
47. Kew S, Banerjee T, Minihane AM, Finnegan YE, Muggli R, Albers R, Williams CM, Calder PC. Lack of effect of foodsenriched with plan-or marine-derived n-3 fatty acids onhuman immune function. Am J Clin Nutr. 2003;77:1287-95.
48. Miles EA, Banerjee T, Dooper MM, M'Rabet L, Graus YM, Calder PC. The influence of different combinations ofgamma-linolenic acid, stearidonic acid and EPA on immunefunction in healthy young male subjects. Brit J Nutr.2004;91:893-903.
49. Calder PC, Newsholme EA. Polyunsaturated fatty acidssuppress human peripheral blood lymphocyte proliferationand interleukin-2 production. Clin Sci. 1992;82:695-700.
50. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation:dual anti-inflammatory and pro-resolution lipid mediators. Nature Rev Immunol. 2008;8:349-61.
51. Simopoulos AP. ômega-6/omega-3 essential fatty acid ratioand chronic diseases. Food Rev Int. 2004;20:36-54.